A robust workforce, flourishing clinical trials, broad patient registries, and consensus treatment protocols contribute to improvements for the subspecialty
2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
Studies determine that both RA and PsA are autoimmune diseases and link disease susceptibility to certain alleles that encode the major histocompatibility complex, HLA
2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
Funding by the Rheumatology Research Foundation has furthered studies on the impact of infectious agents and autoantigens, periodontal disease, and disease-modifying antirheumatic drugs on patients with RA
2013 ACR/ARHP Annual Meeting: New Tools to Measure Quality in Rheumatology
Rising healthcare costs, shifting market forces will require rheumatologists to adapt new quality measurement techniques, more effective patient care models, better rheumatology registries
2013 ACR/ARHP Annual Meeting: Health Professionals In the Spotlight
ARHP members are honored with awards for research, education, advocacy, and patient care in rheumatology
2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate
Discussion by rheumatologists on the merits of biologics vs. triple therapy for patients with RA lends insight into therapeutic alternatives
2013 ACR/ARHP Annual Meeting: Rheumatology Year in Review
Progress in treatments for pediatric rheumatic diseases, collaborative clinical trials, and personalized therapeutic approaches highlight the past year in rheumatology
2013 ACR/ARHP Annual Meeting: Advances in Genomic Research Demystify, Defeat Disease
Researcher J. Craig Venter, PhD, explains how technological progress in metabiomics may enable scientists to create synthetic, engineered bacteria to counter diseases and manufacture virus-fighting vaccines where they are needed
EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
Guidelines give greater nod to use of combination conventional disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, leave monotherapy with methotrexate as acceptable first-line treatment
My Experience at the ACR Dallas Rheumatology Research Workshop
A second-year rheumatology fellow reflects on lectures and lessons learned at the event
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 102
- Next Page »